Short answer
Candel Therapeutics, Inc. (CADL) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$39M
- −711.2% YoY · −339.1% QoQ
- EPS (diluted)
- −$0.56
- −600.0% YoY · −300.0% QoQ
Source: XBRL data from the Candel Therapeutics, Inc. (CADL) Q2 2026 10-Q on SEC EDGAR. USD.
Candel Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Capital deployment: $85.9M net proceeds from December 2024 follow-on offering
- Outlook: anticipated aglatimagene BLA submission in Q4 2026 and linoserpaturev data expected in Q4 2026
Risk Factors
- No material-change comparison provided; risk section contains carried-forward risks rather than quarter-specific additions
- Funding runway into first quarter of 2028, with $201.6 million cash and $47.8 million six-month net loss
- Trinity debt facility up to $130.0 million, including $50.0 million outstanding, with covenant breaches potentially accelerating repayment
- No approved products or product-sale revenue, leaving commercialization dependent on clinical success and regulatory approvals
- Variable-rate debt exposed to higher interest costs, potentially reducing liquidity and increasing cash outflows
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Candel Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.